Biotechnology - Pharmaceutical

Filter

Current filters:

Pharmaceutical

Popular Filters

176 to 200 of 1004 results

The Medicines Co to acquire ProFibrix but deal hinges on trial results

05-06-2013

US drugmaker The Medicines Company (Nasdaq: MDCO) says it has reached agreement to acquire all of the…

BiotechnologyFibrocapsMergers & AcquisitionsPharmaceuticalProFibrixThe Medicines Company

Biotie buys option to acquire Neurelis, and opportunity for epilepsy candidate

04-06-2013

Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) says that it has obtained an exclusive…

BiotechnologyBiotie TherapiesMergers & AcquisitionsNeurelisNeurologicalNRL-1Pharmaceutical

Government programs play huge role in growth of Turkey's health care market; F&S report

04-06-2013

Government funding, growth and consolidation of the middle class, and the rise in non-communicable diseases…

BiotechnologyEuropeHealthcareMarkets & MarketingPharmaceuticalPolitics

FDA "Fast Track" for Soligenix' SGX942 for oral mucositis in patients with head and neck cancer

03-06-2013

US clinical-stage biopharma firm Soligenix (OTCQB: SNGX) says that its SGX942 development program for…

BiotechnologyNorth AmericaOncologyPharmaceuticalRegulationSGX942Soligenix

Negative late-stage trial results for Sanofi's iniparib and otamixaban

03-06-2013

There was disappointing news from French drug major Sanofi (Euronext: SAN) this morning (June 3), as…

BiotechnologyCardio-vasculariniparibOncologyotamixabanPharmaceuticalResearchSanofi

Roche's Avastin extends lives of cervical cancer patients; positive in glioblastoma

03-06-2013

Data presented from the study, known as GOG240, showed that the addition of Swiss pharma major Roche's…

AvastinBiotechnologyGenentechOncologyPharmaceuticalResearchRoche

Merck Serono collaborates with China's BeiGene on second-generation BRAF Inhibitor

31-05-2013

Merck Serono, a division of Germany's Merck KGaA (MRK: DE), today (May 31) announced that it has signed…

BeiGeneBeiGene-283BiotechnologyLicensingMerck KGaAMerck SeronoOncologyPharmaceutical

Market access barriers for multinationals, but Argentina still offers attractive pharma opportunities

31-05-2013

Several barriers impede market access but the regulatory landscape in Argentina is changing and attractive…

BiotechnologyMarkets & MarketingPatentsPharmaceuticalRegulationSouth America

Melbourne's Life Sciences - another decade in the sun

30-05-2013

Despite the Australian city Melbourne's prestigious heritage in scientific medical research dating back…

Asia-PacificBiotechnologyFinancialPharmaceuticalResearch

Oncothyreon and Array collaborate on anti-HER2 compound ARRY-380

30-05-2013

US biotech firms Oncothyreon (Nasdaq: ONTY) and Array BioPharma (Nasdaq: ARRY) plan to collaborate on…

Array BioPharmaARRY-380BiotechnologyLicensingOncologyOncothyreonPharmaceuticalResearch

Avastin remains preferred DME therapy, despite Lucentis extended label in USA

30-05-2013

Despite the approval of Swiss drug major Roche (ROG: SIX) subsidiary Genentech's Lucentis (ranibizumab…

AvastinBayerBiotechnologyEyleaGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRegeneronRoche

GSK to boost vaccines business with 250 million-euro buy of Swiss firm Okairos

30-05-2013

UK pharma giant GlaxoSmithKline (LSE: GSK) yesterday (May 29) revealed that it has acquired Swiss closely-held…

BiotechnologyGlaxoSmithKlineMergers & AcquisitionsOkairosPharmaceuticalVaccines

RedHill Biopharma views regulatory pathway for RHB-101 in CHF and hypertension

29-05-2013

Emerging Israeli biopharma company RedHill Biopharma (TASE: RDHL) says that it recently concluded a positive…

BiotechnologyCardio-vascularCarvedilolLicensingPharmaceuticalRedHill BiopharmaRegulationResearchRHB-101

Amgen and Astellas link up on drugs for unmet medical needs in Japan

29-05-2013

World leading independent biotech firm Amgen (Nasdaq: AMGN) has joined forces with Japanese drug major…

AmgenAnti-Arthritics/RheumaticsAsia-PacificAstellas PharmaBiotechnologyCardio-vascularOncologyPharmaceuticalResearch

Exec appointments at Biogen Idec and Halozyme; Succession plan for Forest Labs

23-05-2013

US biotech firm Biogen Idec (Nasdaq: BIIB) announced that Spyros Artavanis-Tsakonas, has been named chief…

Biogen IdecBiotechnologyForest LaboratoriesHalozyme TherapeuticsManagementPharmaceutical

Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux

23-05-2013

Australian drug developer Alchemia (ASX: ACL) and Merck Serono, a subsidiary of Germany's Merck KGaA…

AlchemiaBiotechnologyErbituxHA-IrinotecanMerck KGaAMerck SeronoOncologyPharmaceuticalResearch

Baxter and Halozyme's HyQvia approved in European Union

22-05-2013

USA-based Baxter International (NYSE: BAX) and Halozyme Therapeutics (Nasdaq: HALO) say that the European…

BaxterBiotechnologyEuropeHalozyme TherapeuticsHyQviaImmunologicalsPharmaceuticalRegulation

Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

22-05-2013

French drug major Sanofi (Euronext: SAN) and US biotech partner Regeneron Pharmaceuticals (Nasdaq: REGN)…

BiotechnologydupilumabPharmaceuticalRegeneronResearchRespiratory and PulmonarySanofi

NICE rejects Avastin for ovarian cancer, but backs Lucentis for RVO

22-05-2013

The UK's drugs watchdog the National Institute for Health and Care Excellence (NICE) has this morning…

AvastinBiotechnologyEuropeLucentisNovartisOncologyOphthalmicsPharmaceuticalPricingRegulationRoche

176 to 200 of 1004 results

Back to top